Vanda Pharmaceuticals Inc — Quarterly Financial Statistics (NASDAQ:VNDA) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics Dividends

Quarterly Annual

Cash from operating activities -14.58 M-1.82 M-33.15 M-15.25 M-31.63 M-29.42 M -109.44 M Cash from investing activities 12.06 M3.99 M43.9 M-15.27 M21.36 M44.87 M 94.86 M Cash from financing activities 0-155 K-1.32 M-425 K-517 K-640 K -2.91 M Free cash flow -14.74 M-2.03 M-33.58 M-15.55 M-31.79 M-29.52 M -110.44 M

Haberler

FDA, Vanda’nın nadir cilt hastalığı başvurusunu kabul etti

Vanda Pharmaceuticals Breaks Through With FDA Approval, Decision Date For Skin Drug - Vanda Pharmaceuticals (NASDAQ:VNDA)

American Express, Oracle among market cap stock movers on Monday

Vanda Pharmaceuticals hisse hedefi FDA onayı sonrası 24 dolara yükseltildi

Vanda Pharmaceuticals stock price target raised to $24 by H.C. Wainwright on FDA approval

Why Is Vanda Pharmaceuticals Stock Soaring On Monday? - Vanda Pharmaceuticals (NASDAQ:VNDA)

Stock Market Today: Dow Jones, S&P 500 Futures Drop After Supreme Court Strikes Down Trump's Emergency Tariffs— Novo Nordisk, Strategy, Vanda In Focus - State Street SPDR S&P 500 ETF Trust (ARCA:SPY)

FDA’nın onayının ardından Vanda Pharmaceuticals hisseleri yükseldi

Vanda Pharmaceuticals stock surges after the FDA approves its new Bipolar I drug

FDA, Vanda’nın Bysanti ilacını bipolar bozukluk için onayladı

FDA approves Vanda’s Bysanti for bipolar disorder, schizophrenia

Vanda Pharmaceuticals Inc. (VNDA) Q4 2025 Earnings Call Transcript